

Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease

Paul J. Mills,* Cyrielle Caussy,^{‡,§} and Rohit Loomba^{‡,||}

*Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California; [‡]NAFLD Research Center, Department of Medicine, La Jolla, California; [§]Université Lyon 1, Hospices Civils de Lyon, Lyon, France; and ^{||}Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, California

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in developed countries.¹ Patients with nonalcoholic steatohepatitis (NASH) are considered to be at a higher risk of fibrosis progression and development to cirrhosis and hepatocellular carcinoma.

Among potential environmental contributors to the pathophysiology of NAFLD are exposure to pesticides and herbicides.² Glyphosate, the primary weed-killing ingredient in Roundup (Monsanto, St Louis, MO), is sprayed on genetically modified crops and on many non-genetically modified grain crops and is found in these crops at harvest.³

Rodents chronically fed with a low dosage of glyphosate exhibit signs of hepatotoxicity, liver congestion, necrosis, and DNA damage of the liver cells.⁴⁻⁶ This study examined excretion levels of glyphosate and its primary metabolite aminomethylphosphonic acid (AMPA) in a well-characterized and prospectively recruited cohort of patients with biopsy-proven NAFLD.

Methods

Participants were originally recruited as part of a larger study between September 2012 and March 2018 at the University of California at San Diego NAFLD Research Center. As previously described,⁷ patients with suspected NAFLD with a clinical indication for liver biopsy underwent a careful evaluation for other causes of hepatic steatosis and liver disease through a standardized research visit including detailed medical and alcohol use history as well as anthropometric and physical examination. Histologic scoring was done using the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System. Before conducting statistical analyses, cases were grouped as definite nonalcoholic steatohepatitis (NASH) or NAFLD not NASH. This study was approved by the University of California at San Diego Institutional Review Board. Informed written consent was obtained from each study participant.

Each patient provided a fasting urine sample that was stored at -80°C . Urine samples were analyzed for

glyphosate and AMPA by using high-performance liquid chromatography coupled with mass spectrometry. Using the formula $[(\text{glyphosate} + 1.5) \times \text{AMPA}]$ we calculated the glyphosate residue, which provides an estimate of dietary intake and exposure to residues.

Analysis of variance, analysis of covariance, χ^2 , and multivariate general linear models covarying for age, gender, and body mass index were used (SPSS Version 24.0 software package; IBM, Armonk, NY). Dependent variables were glyphosate, AMPA, and glyphosate residue. Results were considered statistically significant at the $P \leq .05$ level. Before statistical analyses, data were tested for normality and homogeneity of variance.

Results

Patient characteristics are presented in Table 1. Neither age nor body mass index was significantly related to glyphosate, AMPA, or glyphosate residue. Similarly, neither diabetes status nor race/ethnicity was significantly related to glyphosate, AMPA, or glyphosate residue. Glyphosate (women, $0.373 \mu\text{g/L}$; standard deviation [SD], 0.41 vs men, $0.215 \mu\text{g/L}$; SD, 0.17) ($F = 5.18$; $P = .025$) and glyphosate residue (women, $0.833 \mu\text{g/L}$; SD, 0.67 vs men, $0.594 \mu\text{g/L}$; SD, 0.38) ($F = 4.09$; $P = .046$) were elevated in women as compared with men.

In multivariate models adjusting for age, sex, and body mass index, as compared with patients without NASH, AMPA ($F = 5.39$; $P = .022$) and glyphosate residue ($F = 7.43$; $P = .008$) were elevated in patients with definite NASH (Table 1). When compared with patients without advanced fibrosis (stages 0 and 1), patients with advanced fibrosis (stages 2, 3, and 4) had elevated AMPA

Abbreviations used in this paper: AMPA, aminomethylphosphonic acid; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; SD, standard deviation.

Table 1. Patient Characteristics (Mean ± Standard Deviation)

| | All (n = 97) | Not NASH (n = 34) | Definite NASH (n = 63) | P value ^a |
|--------------------------------------|-------------------------------|-------------------------------|-------------------------------|----------------------|
| Demographics | | | | |
| Age (y) | 50.5 (13.2) (range, 19–74) | 47.3 (12.5) (range, 21–72) | 51.9 (13.8) (range, 19–74) | .249 |
| Male (%) | 41.2 | 53.3 | 36.5 | .124 |
| White (%) | 42.2 | 39.6 | 47.1 | .27 |
| Hispanic or Latino (%) | 35.0 | 35.2 | 34.9 | .81 |
| Body mass index (kg/m ²) | 31.8 (7.0) | 29.2 (3.5) | 33.0 (7.8) | .014 |
| Clinical | | | | |
| Type 2 diabetes (%) | 38.10 | 17.6 | 44.4 | .008 |
| Biological data | | | | |
| AST (U/L) | 47.0 (31.7) | 35.4 (13.2) | 52.5 (36.2) | .014 |
| ALT (U/L) | 65.1 (43.2) | 56.3 (24.8) | 69.3 (48.3) | .179 |
| Hemoglobin A1c (%) | 6.19 (1.2) | 5.71 (0.9) | 6.45 (1.2) | .002 |
| Triglycerides (mg/dL) | 148.4 (66.3) | 168.0 (78.5) | 143.3 (58.8) | .813 |
| Total cholesterol (mg/dL) | 185.0 (46.8) | 195.3 (31.8) | 180.2 (51.9) | .153 |
| HDL cholesterol (mg/dL) | 44.8 (12.9) | 44.2 (10.4) | 45.1 (13.9) | .753 |
| LDL cholesterol (mg/dL) | 106.7 (29.7) | 117.7 (25.0) | 101.8 (30.4) | .020 |
| Platelet count (10 ³ /μL) | 238,880 (72,375) | 238,566 (83,977) | 239,032 (66,794) | .977 |
| Histology | | | | |
| Fibrosis (%) | (n = 74) | (n = 27) | (n = 47) | <.001 |
| Stage 0 | 39.0 | 88.9 | 10.6 | |
| Stage 1 | 5.40 | 3.70 | 6.4 | |
| Stage 2 | 27.1 | 3.70 | 40.4 | |
| Stage 3 | 23.1 | 3.70 | 34.1 | |
| Stage 4 | 5.40 | 0 | 8.5 | |
| Steatosis (%) | (n = 97) | (n = 34) | (n = 63) | .017 |
| Stage 0 | 0.1 | 0 | 1.5 | |
| Stage 1 | 37.7 | 60.1 | 26.6 | |
| Stage 2 | 39.3 | 23.3 | 47.4 | |
| Stage 3 | 22.9 | 16.6 | 24.5 | |
| Lobular inflammation (%) | (n = 90) | (n = 32) | (n = 58) | .003 |
| Stage 0 | 4.5 | 13.3 | 0 | |
| Stage 1 | 47.7 | 60.0 | 41.4 | |
| Stage 2 | 45.5 | 23.4 | 56.9 | |
| Stage 3 | 2.3 | 3.3 | 1.7 | |
| Ballooning (%) | (n = 97) | (n = 34) | (n = 63) | <.001 |
| Stage 0 | 38.7 | 84.7 | 13.3 | |
| Stage 1 | 46.3 | 15.3 | 63.4 | |
| Stage 2 | 15.0 | 0 | 23.3 | |
| Glyphosate excretion | | | | |
| Glyphosate (μg/L) | 0.308 (0.34) | 0.241 (0.18) | 0.344 (0.40) | .164 |
| AMPA (μg/L) | 0.284 (0.28) | 0.197 (0.18) | 0.331 (0.31) | .022 |
| Glyphosate residue (μg/L) | 0.735 (0.58) | 0.538 (0.35) | 0.841 (0.65) | .008 |

NOTE. Data are provided as mean values ± standard deviation or %. Not NASH group defined as patients with NAFL (n = 24) and borderline NASH (n = 10) as opposed to patients with definite NASH.

ALT, alanine aminotransferase; AMPA, aminomethylphosphonic acid; AST, aspartate aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

^aP values determined by comparing characteristics of definite NASH as compared with not NASH, using analysis of variance and analysis of covariance or χ^2 test when appropriate to compare categorical variables.

(0.196 μg/L; SD, 0.20 vs 0.365 μg/L; SD, 0.33) (F = 9.44; P = .003), glyphosate residue (0.525 μg/L; SD, 0.38 vs 0.938 μg/L; SD, 0.372) (F = 11.9; P = .001), and glyphosate (0.230 μg/L; SD, 0.19 vs 0.351 μg/L; SD, 0.45) (F = 4.13; P = .046), respectively.

Discussion

We report that glyphosate excretion is significantly higher in patients with NASH compared with patients without NASH. In addition, we also report a significant

dose-dependent increase of glyphosate exposure with increase in fibrosis stages.

For individuals not working in the agricultural or horticultural industries, the primary route of glyphosate exposure is through ingestion of Roundup-treated genetically modified foods and/or non-genetically modified crops such as wheat and oats.³ Glyphosate excretion was elevated in women, which presumably reflected an increased exposure to glyphosate.

Although there are strengths to this study, including the use of a well-characterized cohort using liver biopsy for the diagnosis of NASH and stage of liver fibrosis, we

acknowledge limitations, including no information on dietary intake or occupation and no patients without NAFLD. We did not find an association between glyphosate excretion and body mass index, suggesting that glyphosate intake was independent of total caloric intake.

As far as potential mechanisms of glyphosate on the liver, Mesnage et al⁴ showed that rats fed glyphosate have disrupted liver mitochondrial oxidative phosphorylation, leading to proteome disturbances reflecting peroxisomal proliferation, steatosis, and necrosis, a profile consistent with NAFLD and its progression to NASH. Other studies show that glyphosate inhibits fatty acid oxidation and increases fat and cholesteryl ester levels in mice livers, leading to increased lipid mass per gram of liver.⁸

References

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. *Nat Rev Gastroenterol Hepatol* 2013;10:686–690.
2. Yang JS, Park Y. Insecticide exposure and development of nonalcoholic fatty liver disease. *J Agric Food Chem* 2018; 66:10132–10138.
3. Myers JP, Antoniou MN, Blumberg B, et al. Concerns over use of glyphosate-based herbicides and risks associated with exposures: a consensus statement. *Environ Health* 2016;15:19.
4. Mesnage R, Renney G, Seralini GE, et al. Multiomics reveal non-alcoholic fatty liver disease in rats following chronic exposure to an ultra-low dose of Roundup herbicide. *Sci Rep* 2017;7:39328.
5. Mesnage R, Arno M, Costanzo M, et al. Transcriptome profile analysis reflects rat liver and kidney damage following chronic ultra-low dose Roundup exposure. *Environ Health* 2015; 14:70.
6. Milic M, Zunec S, Micek V, et al. Oxidative stress, cholinesterase activity, and DNA damage in the liver, whole blood, and plasma of Wistar rats following a 28-day exposure to glyphosate. *Arh Hig Rada Toksikol* 2018;69:154–168.
7. Caussy C, Hsu C, Lo MT, et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. *Hepatology* 2018.
8. Bonvallot N, Canlet C, Blas YEF, et al. Metabolome disruption of pregnant rats and their offspring resulting from repeated exposure to a pesticide mixture representative of environmental contamination in Brittany. *PLoS One* 2018; 13:e0198448.

Reprint requests

Address requests for reprints to: Paul J. Mills, PhD, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0725. e-mail: pmills@ucsd.edu; fax: ■■■■.

Conflicts of interest

The authors disclose no conflicts.

Funding

P.M. receives funding support from NHLBI (R01HL136407) and NCATS (5UL1TR001442). R.L. receives funding support from NIEHS (5P42ES010337), NCATS (5UL1TR001442), and NIDDK (R01DK106419). Support for this study was provided by the Solomon Dutka Fund in the New York Community Trust, the Caroline McKissick Young Foundation, and the Westreich Foundation.